Hansoh Pharmaceutical's HS-10374 meets co-primary endpoints in Phase III plaque psoriasis trial
Medical News||1 分钟阅读
核心洞察
Hansoh Pharmaceutical (搜索) reported that its investigational drug HS-10374 met both co-primary endpoints in a Phase III trial in plaque psoriasis (搜索).
The announcement covers a late-stage study of HS-10374 in plaque psoriasis (搜索), a chronic inflammatory skin condition.
No efficacy data, safety findings, patient numbers or regulatory filing timelines were disclosed in the available report.
Hansoh Pharmaceutical (搜索) said HS-10374 met its co-primary endpoints in a Phase III trial in plaque psoriasis (搜索), according to a Reuters report.
The company did not disclose the specific endpoint results, effect sizes, safety data or the number of patients enrolled in the study in the available report.
Full article: Reuters via TradingView